Rapport Therapeutics shares surge 140.25% in premarket after positive phase 2a trial results for RAP-219.

Rapport Therapeutics, Inc. surged 140.25% in premarket trading after announcing that its Phase 2a clinical trial for focal onset epilepsy met its primary endpoint, with a 77.8% median reduction in patient seizure frequency and 24% achieving seizure freedom. The company, a clinical-stage biotech firm focused on developing small molecule precision drugs for neurological or psychiatric disorders, plans to meet with the FDA in the fourth quarter of 2025 to discuss the Phase 2 end-of-study meeting. H.C. Wainwright also raised its price target for Rapport to $34 from $31, reflecting institutional recognition.